25 research outputs found
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΊ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈΠΈ Π·Π°ΡΡΠ±Π΅ΠΆΠΎΠΌ
The article analyzes current classifications of topical glucocorticosteroid drugs. It also describes advantages and disadvantages of current classifications, emphasizes the expediency of assessing not only the efficacy of the active ingredient but also its skin concentration
taking into consideration the base, trade name of the drug and particular features of its biotransformation in the skin.ΠΠ°Π½ Π°Π½Π°Π»ΠΈΠ· ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΡ
ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΡΠ²Π΅ΡΠ΅Π½Ρ Π΄ΠΎΡΡΠΎΠΈΠ½ΡΡΠ²Π°
ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ
ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ. ΠΡΠΌΠ΅ΡΠ΅Π½Π° ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²Π΅ΡΠ΅ΡΡΠ²Π°, Π΅Π³ΠΎ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π² ΠΊΠΎΠΆΠ΅ Ρ ΡΡΠ΅ΡΠΎΠΌ ΠΎΡΠ½ΠΎΠ²Ρ, ΠΊΠΎΠΌΠΌΠ΅ΡΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π²Π°Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ
Π±ΠΈΠΎΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ Π² ΠΊΠΎΠΆΠ΅
ΠΠΈΠΊΡΠΎΠ±Π½Π°Ρ ΡΠΊΠ·Π΅ΠΌΠ°: ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ»ΡΡΠ°ΡΠΈΠ°Π·ΠΎΠ»Π° ΡΠ΅ΡΠ΅Π±ΡΠ°
Goal. The authors conducted a comparative assessment of the efficacy and safety of 2% silver sulfathiazole in a prospective parallel-group observational study of patients with microbial eczema at the exacerbation stage. Materials and methods. The efficacy of the therapy was assessed on Day 7 and Day 14 based on dynamic calculations of the EASI index and ultrasonic assessment of the intensity of pathological processes in the epidermis and derma; the life quality was assessed based on DLQI and EQ-5D indices, respectively. The microbial composition in the lesions was assessed based on bacterioscopy tests of the contents of blains and erosion fluids. The safety of the therapy was assessed based on the frequency of adverse effects. Results. The administration of 2% silver sulfathiazole arrested both eczematous and pyogenic processes in the lesions within a short period of time, which was confirmed by ultrasonic tests: the depth and density of epidermis and derma were normalized. When applications were performed twice a day, the efficacy with regard to gram-positive bacteria was higher as compared to βclassicalβ topical antibiotics. An evident therapeutic effect with regard to gram-positive bacteria and absence of adverse effects substantially improved the life quality of patients suffering from microbial eczema.ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ 2% ΡΡΠ»ΡΡΠ°ΡΠΈΠ°Π·ΠΎΠ»Π° ΡΠ΅ΡΠ΅Π±ΡΠ° Π² ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π² ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π»ΠΈΡ Ρ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠΉ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ Π² ΡΠ°Π·Π΅ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡ. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Π½Π° 7-ΠΉ ΠΈ 14-ΠΉ Π΄Π½ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ΅ΡΠ° ΠΈΠ½Π΄Π΅ΠΊΡΠ° EASI ΠΈ ΡΠ»ΡΡΡΠ°ΡΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² Π² ΡΠΏΠΈΠ΄Π΅ΡΠΌΠΈΡΠ΅ ΠΈ Π΄Π΅ΡΠΌΠ΅; ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ - ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² DLQI ΠΈ EQ-5D. Π ΡΠΎΡΡΠ°Π²Π΅ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π² ΠΎΡΠ°Π³Π°Ρ
ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΡΠ΄ΠΈΠ»ΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΠ΄Π΅ΡΠΆΠΈΠΌΠΎΠ³ΠΎ ΠΏΡΡΡΡΠ» ΠΈ ΠΎΡΠ΄Π΅Π»ΡΠ΅ΠΌΠΎΠ³ΠΎ ΡΡΠΎΠ·ΠΈΠΉ. ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΡΡΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΡ
ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ². ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ 2% ΡΡΠ»ΡΡΠ°ΡΠΈΠ°Π·ΠΎΠ»Π° ΡΠ΅ΡΠ΅Π±ΡΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ»ΠΎ Π² ΠΊΠΎΡΠΎΡΠΊΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΊΡΠΏΠΈΡΠΎΠ²Π°ΡΡ ΠΊΠ°ΠΊ ΡΠΊΠ·Π΅ΠΌΠ°ΡΠΎΠ·Π½ΡΠ΅, ΡΠ°ΠΊ ΠΈ ΠΏΠΈΠΎΠ³Π΅Π½Π½ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ Π² ΠΎΡΠ°Π³Π°Ρ
ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ, ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π»ΠΎΡΡ ΡΠ»ΡΡΡΠ°ΡΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΡΠΎΠ»ΡΠΈΠ½Ρ ΠΈ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΡΠΏΠΈΠ΄Π΅ΡΠΌΠΈΡΠ° ΠΈ Π΄Π΅ΡΠΌΡ. ΠΡΠΈ Π΄Π²ΡΠΊΡΠ°ΡΠ½ΠΎΠΌ Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½ΠΎΠΌ Π½Π°Π½Π΅ΡΠ΅Π½ΠΈΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π³ΡΠ°ΠΌΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠΈΠΊΡΠΎΠ±Π½ΡΡ
Π°Π³Π΅Π½ΡΠΎΠ² Π±ΡΠ»Π° Π²ΡΡΠ΅ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Ρ Β«ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β» ΠΌΠ΅ΡΡΠ½ΡΡ
Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ². ΠΡΡΠ΅ΡΠ»ΠΈΠ²ΡΠΉ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ Π³ΡΠ°ΠΌΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°Π²Π° ΠΌΠΈΠΊΡΠΎΡΠ»ΠΎΡΡ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ»ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠΉ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π£Π€Π1-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ²
The authors present the results of application of UVA1-therapy in complex treatment of patients with atopic dermatitis, psoriasis and scleroderma. Course of treatment has made 20 procedures of UVA1-therapy with the maximum single dose of irradiation 40 J/Ρ 2. The general dose of an irradiation 130β400 J/Ρ 2. Comparison groups received medical therapy with usage of standard doses and reception schemes, and did not differ from the basic groups on age of patients, duration and the disease form. Clinical efficiency estimated on dynamics of indexes SCORAD, PAS! and results of ultrasonic scanning of the scleroderma zones. High efficiency and safety of UVA1-therapy in complex treatment atopic dermatitis, psoriasis and scleroderma is established.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ, ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ Π΄Π°Π»ΡΠ½Π΅ΠΉ Π΄Π»ΠΈΠ½Π½ΠΎΠ²ΠΎΠ»Π½ΠΎΠ²ΠΎΠΉ Π£Π€-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π£Π€Π1). ΠΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ» 20 ΠΏΡΠΎΡΠ΅Π΄ΡΡ Π£Π€Π1-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ 40 ΠΠΆ/ΡΠΌ 2. ΠΠ±ΡΠ°Ρ Π΄ΠΎΠ·Π° ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ 130β400 ΠΠΆ/ΡΠΌ 2. ΠΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ
Π΄ΠΎΠ· ΠΈ ΡΡ
Π΅ΠΌ ΠΏΡΠΈΠ΅ΠΌΠ° ΠΈ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΈΡΡ ΠΎΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π³ΡΡΠΏΠΏ ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΠΎΡΠΌΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² SCoRAD, PASI, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ³ΠΎ ΡΠΊΠ°Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠ°Π³ΠΎΠ² ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π£Π€Π1-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΠΈ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
ΠΠ»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π°ΠΊΠ½Π΅: Π²ΡΠ±ΠΎΡ Π΄ΠΎΠ· ΠΈ ΡΡ Π΅ΠΌ ΠΏΡΠΈΠ΅ΠΌΠ° ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½Π°
The article presents current data on the application of a systemic retinoid, isotretinoin, on the basis of the Lidose system for the treatment of patients with severe forms of acne. It also discusses issues of optimization of the daily dose of isotretinoin taking into consideration long-term clinical efficacy and safety of the therapy. The article presents the results of the authorsβ study demonstrating the possibility to select mainly large or small doses of systemic isotretinoin depending on the treatment duration.ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ΄Π° ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½Π° Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠΈΡΡΠ΅ΠΌΡ Lidose Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Π°ΠΊΠ½Π΅. ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΡΡΡΠΎΡΠ½ΠΎΠΉ Π΄ΠΎΠ·Ρ ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½Π° Ρ ΡΡΠ΅ΡΠΎΠΌ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡΠΈΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π±ΠΎΠ»ΡΡΠΈΡ
, Π»ΠΈΠ±ΠΎ ΠΌΠ°Π»ΡΡ
Π΄ΠΎΠ· ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½Π° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΡΡΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ·ΠΊΠΎΠΏΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅Π΄Π½Π΅Π²ΠΎΠ»Π½ΠΎΠ²ΠΎΠΉ ΡΠ»ΡΡΡΠ°ΡΠΈΠΎΠ»Π΅ΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ 311 Π½ΠΌ ΠΏΡΠΈ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ΅ Ρ Π΄Π΅ΡΠ΅ΠΉ
The article presents the results of using a narrow-band mid-wavelength ultraviolet therapy (311 nm) in 79 children suffering from with atopic dermatitis. The course of treatment comprised 15 to 20 sessions of ultraviolet therapy with the maximal dose of irradiation being not more than 0.15 J/cm2. The control group (n=35) received traditional therapeutic treatment with the use of standard schemes of dosing and drug administration, and did not differ from the main group of patients in age, duration or form of the disease. Clinical efficacy of the therapy was estimated according to the SCORAD index, Dermatological Index of the Symptom Scale and Children's Dermatology Life Quality Index. The efficacy of the narrow-band mid-wavelength ultraviolet therapy (311 nm) turned out to be very high, which is confirmed by earlier reduction of clinical symptoms among patients from this group than in the control group. The latter fact was also confirmed by the reduction of absolute values of the SCORAD index and Dermatological Index of the Symptom Scale (pΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ 79 Π΄Π΅ΡΠ΅ΠΉ, Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, ΡΠ·ΠΊΠΎΠΏΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅Π΄Π½Π΅Π²ΠΎΠ»Π½ΠΎΠ²ΠΎΠΉ Π£Π€Π-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (311 Π½ΠΌ). ΠΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΎΡΡΠΎΡΠ» ΠΈΠ· 15-20 ΠΏΡΠΎΡΠ΅Π΄ΡΡ Π£Π€Π-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (311 Π½ΠΌ) Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ°Π·ΠΎΠ²ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ Π½Π΅ Π±ΠΎΠ»Π΅Π΅ 0,15 ΠΠΆ/ΡΠΌ2. ΠΡΡΠΏΠΏΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ (35 Π±ΠΎΠ»ΡΠ½ΡΡ
) ΠΏΠΎΠ»ΡΡΠ°Π»Π° ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ
Π΄ΠΎΠ· ΠΈ ΡΡ
Π΅ΠΌ ΠΏΡΠΈΠ΅ΠΌΠ° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°Π»Π°ΡΡ ΠΎΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΠΎΡΠΌΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² SCORAD, ΠΠΠ¨Π‘ ΠΈ ΠΠΠΠΠ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ·ΠΊΠΎΠΏΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅Π΄Π½Π΅Π²ΠΎΠ»Π½ΠΎΠ²ΠΎΠΉ Π£Π€Π-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (311 Π½ΠΌ), ΠΎ ΡΠ΅ΠΌ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ Π±ΠΎΠ»Π΅Π΅ ΡΠ°Π½Π½Π΅Π΅, ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ, ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ², ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π»ΠΎΡΡ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π°Π±ΡΠΎΠ»ΡΡΠ½ΡΡ
Π²Π΅Π»ΠΈΡΠΈΠ½ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² SCORAD, ΠΠΠ¨Π‘ (
ΠΠ± ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΈ Π΅Π΅ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ
Goal. To assess the effect of a combined cytostatic therapy and sulodexide on the functional condition of the vascular endothelium in psoriatic patients. Materials and methods. The authors examined 74 patients suffering from psoriasis vulgaris and exudative form of psoriasis. Depending on the treatment option, the patients were subdivided into two groups: Group I (n = 41) receiving a cytostatic therapy and Group II where patients received sulodexide as well. The severity of the endothelium dysfunction was assessed based on laboratory assessments such as nitrogen oxide and endothelin 1 in the blood serum. Results. Prior to the treatment, the level of nitrogen oxide was reduced and endothelin 1 was increased in the blood serum of most patients. Substantial improvement of the pathological process was observed in patients from Group I after the cytostatic therapy (total dose of methotrexate: 100 mg); no normalization of laboratory assessments was observed. In patients from Group II receiving methotrexate (total dose: 40 mg) along with sulodexide, improvement or recovery was observed after the completion of the treatment; endothelium dysfunction was normalized. Conclusion. The inclusion of sulodexide in a complex therapy normalizes endothelial dysfunction in case of psoriasis and reduces the dose and duration of methotrexate treatment.Π¦Π΅Π»Ρ. ΠΡΠ΅Π½ΠΊΠ° Π²Π»ΠΈΡΠ½ΠΈΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΈΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΡΡΠ»ΠΎΠ΄Π΅ΠΊΡΠΈΠ΄Π° Π½Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ ΡΠΎΡΡΠ΄ΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 74 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π²ΡΠ»ΡΠ³Π°ΡΠ½ΠΎΠΉ ΠΈ ΡΠΊΡΡΡΠ΄Π°ΡΠΈΠ²Π½ΠΎΠΉ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π°. Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ: Π±ΠΎΠ»ΡΠ½ΡΠ΅ 1-ΠΉ Π³ΡΡΠΏΠΏΡ (n = 41) ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΠΈΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, Π±ΠΎΠ»ΡΠ½ΡΠΌ 2-ΠΉ Π³ΡΡΠΏΠΏΡ (n = 33) Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ Π² Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π±ΡΠ» Π²ΠΊΠ»ΡΡΠ΅Π½ ΡΡΠ»ΠΎΠ΄Π΅ΠΊΡΠΈΠ΄. ΠΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ - ΠΎΠΊΡΠΈΠ΄Π° Π°Π·ΠΎΡΠ° ΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ½Π°-1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΎΠΊΡΠΈΠ΄Π° Π°Π·ΠΎΡΠ° ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ½Π°-1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ. ΠΠ½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
1-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΠΏΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠΈΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ Π΄ΠΎΠ·Π° ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ° 100 ΠΌΠ³), ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ ΠΊ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π΅ Π±ΡΠ»ΠΎ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
2-ΠΉ Π³ΡΡΠΏΠΏΡ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°Ρ (ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ Π΄ΠΎΠ·Π° 40 ΠΌΠ³) Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ΅ Ρ ΡΡΠ»ΠΎΠ΄Π΅ΠΊΡΠΈΠ΄ΠΎΠΌ, ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΠ°, Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΡΠ»ΠΎΠ΄Π΅ΠΊΡΠΈΠ΄Π° Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΡΠ΅Ρ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΡ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ ΠΏΡΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π΅ ΠΈ ΠΏΠΎΠΌΠΎΠ³Π°Π΅Ρ ΡΠΌΠ΅Π½ΡΡΠΈΡΡ Π΄ΠΎΠ·Ρ ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈΠ΅ΠΌΠ° ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ°
ΠΠΈΠΌΡΠΎΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΉ ΠΏΠ°ΠΏΡΠ»Π΅Π·
Etiology, pathogenesis, clinical and pathomorphological criteria of diagnostics of lymphomatoid papulosis are described. The case of own supervision is presented.ΠΠΏΠΈΡΠ°Π½Ρ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π»ΠΈΠΌΡΠΎΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ°ΠΏΡΠ»Π΅Π·Π°, ΠΏΡΠΈΠ½ΡΠΈΠΏΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½ ΡΠ»ΡΡΠ°ΠΉ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
ΠΠΈΠΏΠΎΠΈΠ΄Π½ΡΠΉ Π½Π΅ΠΊΡΠΎΠ±ΠΈΠΎΠ· (Π±ΠΎΠ»Π΅Π·Π½Ρ ΠΠΏΠΏΠ΅Π½Π³Π΅ΠΉΠΌΠ° β ΡΡΠ±Π°Ρ Π°)
Etiology, pathogenesis, clinical and pathomorphological criteria of diagnostics of necrobiosis lipoidica are described. The case of own supervision is presented.ΠΠΏΠΈΡΠ°Π½Ρ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π»ΠΈΠΏΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ Π½Π΅ΠΊΡΠΎΠ±ΠΈΠΎΠ·Π°, ΠΏΡΠΈΠ½ΡΠΈΠΏΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½ ΡΠ»ΡΡΠ°ΠΉ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
INTERFERON BETA IN TREATMENT OF DISSEMINATED SCLEROSIS IN ADOLESCENTS β INFLUENCE ON NEUROPSYCHOLOGICAL STATUS AND PAROXYSMAL STATES
Disseminated sclerosis is chronic progressive disease of central nervous system, which is characterized by demyelination, degeneration of nerve fibers and polymorphous clinical symptoms. According to literature data, 2β10% of patients have onset of a disease in childhood and adolescence. Frequent clinical symptoms of disseminated sclerosis, especially in adolescents, are paroxysmal states and neuropsychological disorders. Drugs containing interferon beta which are used for immunomodulating treatment, can increase the rate of paroxysmal neuropsychological disorders in patients with disseminated sclerosis. Present study with participation of 78 adolescents analyzed frequency and spectrum of neuropsychological disorders and paroxysmal states in patients 12β17 years old and relation of revealed disorders with a treatment with interferon beta.Key words: adolescents, disseminated sclerosis, interferon beta, treatment, depression, paroxysmal states, anxiety, neuropsychological testing.(Voprosy sovremennoi pediatrii βΒ Current Pediatrics. β 2010;9(4):34-39)</span
SAFETY OF INTERFERON BETA 1A FOR A SUBCUTANEOUS ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH DISSEMINATED SCLEROSIS
The onset of disseminated sclerosis occurs in childhood and juvenile age in 10% of patients. nevertheless, all immunomodulatory drugs for a treatment of this disease intended for adult population of patients, and there's an age limitation to the administration of these medications. There's only one interferon beta in group of Β«changing the clinical course of disseminated sclerosis medicationsΒ», that was annotated to the administration in patients from 16 years. It's interferon betab1a (Rebif) for subcutaneous administration in 22 ?g and 44 ?g dosage. This drug was well known as an effective and safe medication for a long term administration for a long time in adult neurological practice. But doctors have to use interferon betab1a Β«off labelΒ» yet in patients younger 16 years in Russia and in other countries, comparing risk of changing the regimen of age limitation and risk of deprivation of un derbaged patient of years of qualitative life.Key words: children, disseminated sclerosis, interferon beta 1a, treatment